April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Neuroprotective Effects of Agmatine on Ischemia-Reperfusion-Induced Retinal Ganglion Cell Damage by Transient Middle Cerebral Artery Occlusion
Author Affiliations & Notes
  • S. Hong
    Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • H. Hara
    Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan
  • M. Shimazawa
    Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan
  • C. Kim
    Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • G. Seong
    Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  S. Hong, None; H. Hara, None; M. Shimazawa, None; C. Kim, None; G. Seong, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3171. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Hong, H. Hara, M. Shimazawa, C. Kim, G. Seong; Neuroprotective Effects of Agmatine on Ischemia-Reperfusion-Induced Retinal Ganglion Cell Damage by Transient Middle Cerebral Artery Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3171.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate neuroprotective effects of agmatine on ischemia-reperfusion-induced damage in retinal ganglion cells (RGCs).

Methods: : A total of 32 adult male ddY mice were used for this study. The ocular ischemia was induced by intraluminal middle cerebral artery occlusion (MCAO), which causes an occlusion of the ophthalmic artery as well as the middle cerebral artery. Mice in the agmatine group were treated once with an intraperitoneal injection of agmatine (100 mg/kg) 30 minutes before MCAO.

Results: : After two hours MCAO and 22 hours of reperfusion, the proportion of pyknotic cells within the RGC layer increased from 0 % to 38.67 ± 0.80 %. When 100 mg/kg agmatine was injected intraperitonally 30 minutes before MCAO, the proportion of pyknotic RGCs was significantly reduced to 14.11 ± 0.47 % (p<0.001).

Conclusions: : Agmatine reduces ischemia-reperfusion-induced RGC damage caused by transient MCAO. It has the potential to become a new therapeutic option for treating ocular diseases associated with ischemic injury.

Keywords: ganglion cells • ischemia • neuroprotection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×